Novartis | NVS

Stock Price
129.82
Daily Change
1.34 1.04%
Monthly
14.38%
Yearly
11.22%
Q3 Forecast
128.96

Peers Price Chg Day Year Date
AbbVie 212.56 -0.44 -0.21% 9.95% Sep/05
Amgen 283.64 3.54 1.26% -11.49% Sep/05
AstraZeneca 12,090.00 -98.00 -0.80% -4.89% Sep/06
Biogen 140.67 0.73 0.52% -30.02% Sep/05
Bristol-Myers Squibb 47.14 0.45 0.96% -3.28% Sep/05
Corcept Therapeutics 69.36 -0.01 -0.01% 101.75% Sep/05
Gilead Sciences 115.05 2.28 2.02% 46.10% Sep/05
GlaxoSmithKline 1,476.00 7.00 0.48% -10.63% Sep/05
Glaxosmithkline 40.50 0.89 2.25% -7.26% Sep/05
J&J 178.43 -0.33 -0.18% 8.51% Sep/05
Eli Lilly 727.21 -15.70 -2.11% -19.48% Sep/05
Merck 84.71 0.66 0.79% -28.14% Sep/05
Novartis 129.82 1.34 1.04% 11.22% Sep/05
Prestige Brands 65.05 -1.70 -2.55% -12.50% Sep/05
Pacira 26.45 -0.28 -1.05% 90.97% Sep/05
Pfizer 24.88 0.34 1.39% -12.95% Sep/05
Perrigo 23.49 -0.25 -1.05% -19.14% Sep/02
Drreddys Laboratories 14.34 0.19 1.34% -81.89% Sep/05
Roche Holding 274.20 -1.50 -0.54% 2.62% Sep/06
Sanofi 79.50 0.54 0.68% -24.83% Sep/06
Sanofi 46.50 1.18 2.60% -19.47% Sep/05
Supernus Pharmaceuticals 46.00 0.57 1.25% 35.93% Sep/05
Bausch Health Companies 10.18 0.20 2.00% 20.90% Sep/05
Canopy Growth 2.02 0.11 5.76% -66.72% Sep/05
Zoetis 153.32 0.12 0.08% -19.13% Sep/05


Novartis traded at $129.82 this Friday September 5th, increasing $1.34 or 1.04 percent since the previous trading session. Looking back, over the last four weeks, Novartis gained 14.38 percent. Over the last 12 months, its price rose by 11.22 percent. Looking ahead, we forecast Novartis to be priced at 128.96 by the end of this quarter and at 126.43 in one year, according to Trading Economics global macro models projections and analysts expectations.

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.